亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.

奥佐美星 卡奇霉素 医学 耐受性 中性粒细胞减少症 CD33 髓系白血病 药理学 免疫结合物 肿瘤科 内科学 免疫学 不利影响 毒性 单克隆抗体 干细胞 川地34 抗体 生物 遗传学
作者
Peter F. Bross,Julie G. Beitz,Gang Chen,Xi Chen,Eamon J Duffy,L V Kieffer,S Roy,R N Sridhara,A Rahman,G Williams,Richard Pazdur
出处
期刊:PubMed [National Institutes of Health]
卷期号:7 (6): 1490-1496 被引量:870
链接
标识
摘要

PURPOSE: Gemtuzumab ozogamicin (Mylotarg; Wyeth Laboratories, Philadelphia, PA) consists of a semisynthetic derivative of calicheamicin, a cytotoxic antibiotic linked to a recombinant monoclonal antibody directed against the CD33 antigen present on leukemic myeloblasts in most patients with acute myeloid leukemia (AML). In this study, we review the preclinical and clinical profiles of this immunoconjugate and the regulatory review that led to marketing approval by the United States Food and Drug Administration. EXPERIMENTAL DESIGN: From the literature and manufacturer's data, we review the activity, tolerability, and pharmacokinetics of gemtuzumab ozogamicin in preclinical and Phase I studies and its activity, efficacy, and side effects in three Phase 2 trials of 142 patients with relapsed AML. RESULTS: In Phase I studies, the major toxicity was myelosuppression, especially neutropenia and thrombocytopenia, resulting from the expression of CD33 on myeloid progenitor cells. The Phase 2 dose was 9 mg/m(2) infused i.v. over 4 h, repeated on day 14. A minority of patients experienced acute infusion-related symptoms, usually transient and occasionally requiring hospitalization. The complete response (CR) rate with full recovery of hematopoiesis was 16%. A subset of patients [CRs with incomplete platelet recovery (CRps)] was identified with blast clearance and neutrophil recovery but incomplete platelet recovery. The duration of responses of CRps appeared to be similar to those of the CRs, although the numbers were small. The question of the equivalence of these response groups was a central issue in the review of this new drug application (NDA). After considerable discussion, the Oncology Drugs Advisory Committee recommended allowing inclusion of CRps resulting in an overall response rate in the Phase 2 studies of 30%. In the subgroup of patients over 60 years of age, the overall response rate was 26%. Response duration was difficult to establish because of the high prevalence of postremission therapies. Tolerability and ease of administration may be improved compared with conventional chemotherapy, except for hepatotoxicity, with 31% of patients exhibiting abnormal liver enzymes. One patient died of liver failure in the Phase 2 trials. CONCLUSIONS: Marketing approval of gemtuzumab ozogamicin was granted on May 17, 2000 by the United States Food and Drug Administration under the Accelerated Approval regulations. Gemtuzumab ozogamicin is indicated for the treatment of patients with CD33 positive AML in first relapse who are 60 years of age or older and who are not considered candidates for cytotoxic chemotherapy. The approved dose was 9 mg/m(2) i.v. over 4 h and repeated in 14 days. Completion of the ongoing studies of gemtuzumab ozogamicin in relapsed AML and initiation of randomized clinical trials comparing the effects of gemtuzumab ozogamicin in combination with conventional induction chemotherapy to conventional chemotherapy alone on survival are mandated to confirm clinical benefit under the accelerated approval Subpart H regulations. Postmarketing reports of fatal anaphylaxis, adult respiratory distress syndrome (ARDS), and hepatotoxicity, especially venoocclusive disease (VOD) in patients treated with gemtuzumab ozogamicin, with and without associated hematopoietic stem cell transplantation (HSCT), have required labeling revisions and the initiation of a registration surveillance program. Tumor lysis and ARDS have been reported in patients with leukocytes above 30,000/ml treated with gemtuzumab ozogamicin; therefore, the reduction of leukocyte counts to below 30,000/ml is recommended prior to treatment. Patients should be carefully monitored for acute hypersensitivity, hypoxia, and delayed hepatotoxicity following treatment with gemtuzumab ozogamicin.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
c_phoebe完成签到,获得积分10
6秒前
12秒前
14秒前
30秒前
懵懂的念波完成签到,获得积分10
30秒前
32秒前
痴情的归尘完成签到,获得积分10
32秒前
33秒前
38秒前
桐桐的应助被南宫雪采纳,获得10
41秒前
zzz完成签到,获得积分10
44秒前
科目三的应助被科研通管家采纳,获得10
49秒前
49秒前
充电宝的应助被科研通管家采纳,获得10
49秒前
null的应助被科研通管家采纳,获得10
49秒前
Orange的应助被科研通管家采纳,获得10
50秒前
英俊的铭的应助被科研通管家采纳,获得10
50秒前
53秒前
忧郁思远完成签到,获得积分10
54秒前
57秒前
teyr完成签到,获得积分10
1分钟前
机灵的夜梅完成签到,获得积分10
1分钟前
Pikachu完成签到,获得积分10
1分钟前
1分钟前
高大的紫萍完成签到,获得积分10
1分钟前
小祝没吃饱完成签到,获得积分10
1分钟前
1分钟前
1分钟前
天真的音完成签到,获得积分10
1分钟前
陳源完成签到 ,获得积分10
1分钟前
ABC完成签到,获得积分10
1分钟前
芋头完成签到,获得积分10
2分钟前
2分钟前
复杂鸵鸟完成签到,获得积分10
2分钟前
2分钟前
Younger发布了新的文献求助10
2分钟前
2分钟前
忧郁依柔完成签到,获得积分10
2分钟前
2分钟前
2分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158694
求助须知:如何正确求助?哪些是违规求助? 9554462
关于积分的说明 21719198
捐赠科研通 7748257
什么是DOI,文献DOI怎么找? 3427070
关于科研通互助平台的介绍 2551949
邀请新用户注册赠送积分活动 2471308